Khosravi Malihe, Taghvaye Masoumi Hamidreza, Gholami Kheirollah, Vaezi Mohammad, Hadjibabaei Molouk, Ghavamzadeh Ardeshir
Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Int J Hematol Oncol Stem Cell Res. 2018 Oct 1;12(4):318-321.
Cancer-related fatigue (CRF) is a very prominent complaint and disabling symptom in cancer patients probably influenced by endogenous cytokines. But, the published data on this subject are limited. We explored the relationship of cytokines such as tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) with fatigue in patients with AML. This study was performed on 45 patients (25 men, 20 women) with newly diagnosed AML. We examined fatigue in these patients with validated questionnaire. Simultaneously, blood samples were obtained for quantitative measurement of IL-6 and TNF-α. Our results showed a positive correlation between fatigue and circulating levels of IL-6 (P=0.004, R=0.416). Many patients with AML experienced severe fatigue before the onset of treatment, which is not related to their hemoglobin (Hb) levels. Cytokine levels may be beneficial markers in resistance to fatigue, but further studies are needed before considering targeted therapies as a treatment for CRF.
癌症相关性疲劳(CRF)是癌症患者中一种非常突出的主诉和致残症状,可能受内源性细胞因子影响。但是,关于这一主题的已发表数据有限。我们探讨了肿瘤坏死因子(TNF-α)和白细胞介素-6(IL-6)等细胞因子与急性髓系白血病(AML)患者疲劳之间的关系。本研究对45例新诊断的AML患者(25例男性,20例女性)进行。我们用经过验证的问卷对这些患者的疲劳情况进行了检查。同时,采集血样用于定量检测IL-6和TNF-α。我们的结果显示疲劳与IL-6的循环水平呈正相关(P = 0.004,R = 0.416)。许多AML患者在治疗开始前就经历了严重的疲劳,这与他们的血红蛋白(Hb)水平无关。细胞因子水平可能是抗疲劳的有益标志物,但在将靶向治疗作为CRF的一种治疗方法之前,还需要进一步研究。